Creatinine news

All news on Creatinine (also known as 2-Amino-1-methyl-5H-imidazol-4-one): plants, production capacities, investments and involved companies.

24 August 2026

Sobi Japan and Asahi Kasei: Empaveli approved in Japan for C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis

First complement inhibitor in Japan for patients aged 12+ with these rare kidney diseases; VALIANT showed 68.1% proteinuria reduction and eGFR stabilization versus placebo.

Who will be producing Creatinine in the future?

Find out with chemXplore Alpha

Learn more